Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript Summary
Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript Summary
Adjusted gross margin increased slightly to 61% from 60% the previous year, with EluPro and CanGaroo achieving a gross margin of 68% and SimpliDerm at 56%.The following is a summary of the Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript:
以下是Elutia Inc. (ELUT) 2024年第三季度業績會議電話交易摘要：
Financial Performance:
財務表現：
Elutia reported Q3 revenue of $5.9 million, a slight decrease from $6.1 million in the same quarter last year.
SimpliDerm grew 19% this quarter with sales of $3.1 million.
Adjusted gross margin increased slightly to 61% from 60% the previous year, with EluPro and CanGaroo achieving a gross margin of 68% and SimpliDerm at 56%.
Operating expenses rose to $13 million from $10 million, largely due to non-cash stock-based compensation expense.
The company reported a net income of $1.3 million for the quarter, influenced by non-cash gains from warrant revaluations.
Adjusted EBITDA showed a loss of $2.9 million, up from $1.7 million in the previous year.
Elutia報告第三季度營業收入爲590萬美元，略低於去年同期的610萬美元。
SimpliDerm本季度銷售額達到310萬美元，增長19%。
調整後的毛利率略微上升至61%，去年爲60%，EluPro和CanGaroo的毛利率達到68%，而SimpliDerm爲56%。
營業費用從1000萬美元上升至1300萬美元，主要是由於非現金股權激勵支出。
公司報告本季度淨利潤爲130萬美元，受權證重新估值的非現金收益影響。
調整後的EBITDA虧損爲290萬美元，高於去年的170萬美元。
Business Progress:
業務進展：
Elutia is expanding its commercial footprint with strategic additions to its sales force in Southern California and the Northeast.
They have completed over 100 VAC submissions, with 36 accounts actively ordering, reflecting effective market penetration strategies.
EluPro's first commercial use began on September 5th with significant early adoption, already accounting for 25% of ongoing bio envelope sales.
The company continues to advance its GPO strategies with expected favorable coverage decisions in early 2025.
Elutia正在通過戰略性增加南加州和東北部銷售團隊來擴大其商業版圖。
他們已完成100多次VAC提交，並有36個帳戶積極訂購，反映了有效的市場滲透策略。
EluPro的首次商業應用始於9月5日，早期採用率顯著，已佔正在銷售的生物包裝銷售額的25%。
該公司繼續推進其GPO戰略，預計將在2025年初做出有利的覆蓋決定。
Opportunities:
機會：
Elutia is focusing on commercial launch and market expansion for its EluPro product, starting full commercialization in January 2025.
There is increasing adoption of EluPro across major CIED brands, demonstrating market acceptance and potential growth.
EluPro was used for the first neurostimulator device on October 31st, indicating potential for broader application beyond initial targets and opening up new market segments.
Elutia正在專注於其EluPro產品的商業推出和市場擴展，計劃於2025年1月開始全面商業化。
EluPro在主要CIED品牌中的採用率越來越高，展示了市場的接受程度和潛在增長。
EluPro於10月31日首次用於神經刺激器，顯示出超越最初目標的潛力，並打開了新的市場細分領域。
Risks:
風險：
Initial growth from EluPro, while promising, has been described as gradual, noting challenges in scaling and integrating the product into various markets swiftly.
雖然EluPro的初期增長令人鼓舞，但已被描述爲逐漸進行，指出在快速將產品擴展到各個市場並融合其中方面存在挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
